Kevin P. Starr - Jun 10, 2021 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)

Role: Director
Signature: /s/ Jennifer Fitzpatrick, as Attorney-in-Fact for Kevin P. Starr
Stock symbol: SAGE
Transactions as of: Jun 10, 2021
Transactions value $: $0
Form type: 4
Date filed: 6/11/2021, 04:07 PM
Next filing: Jun 17, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SAGE	Stock Option (Right to Buy)	Award	$0	+10K		$0.00	10K	Jun 10, 2021	Common Stock	10K	$76.09	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan in accordance with the terms of the Amended and Restated Non-Employee Director Compensation Policy. The option will vest in full upon the earlier to occur of June 10, 2022 or the day immediately prior to the 2022 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date.

Content

The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan in accordance with the terms of the Amended and Restated Non-Employee Director Compensation Policy. The option will vest in full upon the earlier to occur of June 10, 2022 or the day immediately prior to the 2022 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date.